Search results for: Multi-Indication Medicines
Filter search results
Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
1 February 2016
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…Published online June 2021. Accessed September 30, 2022. https://www.ace-hta.gov.sg/docs/default-source/process-methods/ace-drug-and-vaccine-evaluation-methods-and-process-guide-(june-2021).pdf Danish Medicines Council. The Danish Medicines Council Methods Guide For Assessing New Pharmaceuticals. Published online 2021. Accessed November 9, 2022. https://medicinraadet.dk/media/wq0dxny2/the_danish_medicines_council_methods_guide_for_assessing_new_pharmaceuticals_version_1-…
Advances in Oncology Modelling: Recent Results from POI Research
18 September 2012
…government. The focus of the workshop was three key technical challenges associated with using clinical trial data for anti-cancer medicines and adapting it, in an unbiased fashion, to support decisions…
Spotlight on OHE: EQ-5D-5L, Next Generation Sequencing, and MCDA
19 December 2014
…published in Value in Health (https://www.valueinhealthjournal.com/article/S1098-3015%2813%2904356-8/abstract) An earlier version of the article was published as an OHE research paper and can accessed at https://www.ohe.org/publications/multi-criteria-decision-analysis-value-orphan-medicines For additional information please contact Martina…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…of evaluating, for example, gene-based treatments or medicines paired with diagnostics. For payers, the more targeted treatments require new approaches to HTA and pricing, even pricing by indication in some…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
…Development Association to discuss the process and problems that surround decisions about pricing and reimbursement for innovative oncology medicines in Europe. OHE’s Adrian Towse participated in a two-day workshop convened…
Capturing the Unexpected Benefits of Medical Research
5 January 2001
…This is true for long established medicines, for example the cardiovascular benefits of… It has long been known that a medicine may turn out to have an unexpected beneficial effect…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…data exclusivity (DE), and Supplementary Protection Certificates (SPCs), is seen as important. This is due to the high cost of research and development (R&D) for new medicines and the issue…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
…is in the body. Despite generating a paradigm shift these therapies are faced with multiple challenges to fit the regulatory and health technology assessment frameworks used by healthcare decision-makers. Yet,…